NeuroBo Pharmaceuticals, Inc. (NRBO)
After hours:
| Previous close | 0.6700 |
| Open | 0.6546 |
| Bid | 0.6409 x 3000 |
| Ask | 0.6740 x 1300 |
| Day's range | 0.6231 - 0.6680 |
| 52-week range | 0.5510 - 63.8500 |
| Volume | |
| Avg. volume | 1,078,337 |
| Market cap | 12.422M |
| Beta (5Y monthly) | -0.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -15.2200 |
| Earnings date | 30 Mar 2023 - 03 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.00 |
- PR Newswire
NeuroBo Pharmaceuticals Appoints Joseph Hooker as Interim Chief Executive Officer and President
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced that it has appointed Joseph Hooker as Interim Chief Executive Officer and President.
- PR Newswire
NEUROBO ANNOUNCES CLOSING OF $32.3 MILLION UNDERWRITTEN PUBLIC OFFERING INCLUDING FULL EXERCISE OF OVERALLOTMENT OPTION AND CONCURRENT PRIVATE PLACEMENT
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) ("NeuroBo" or the "Company"), a clinical-stage biotechnology company focused on therapies for cardiometabolic diseases, today announced the closing of an underwritten public offering of units with gross proceeds of approximately $17.3 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by
- PR Newswire
NEUROBO ANNOUNCES PRICING OF $30 MILLION UNDERWRITTEN PUBLIC OFFERING AND CONCURRENT PRIVATE PLACEMENT
NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) (the "Company" or "NeuroBo") today announced the pricing of an underwritten public offering of units and a concurrent private placement for gross proceeds of approximately $30 million prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo.
